News
ARGNF
803.19
NaN%
--
Baron Health Care Fund Q1 2026 Portfolio Activity
Seeking Alpha · 05/27 19:16
Argenx targets 2.5x more VYVGART patients by decade-end as Phase III empasiprubart MMN readout nears 4Q
Seeking Alpha · 05/07 21:12
argenx SE GAAP EPS of $5.52 beats by $0.31, revenue of $1.3B misses by $10M
Seeking Alpha · 05/07 05:11
PGIM Jennison Health Sciences Fund Q4 2025 Key Contributors And Detractors
Seeking Alpha · 03/16 03:25
Baron International Growth Fund Q4 2025: Contributors, Detractors, And Trades
Seeking Alpha · 02/27 11:50
Artisan Global Discovery Fund Q4 2025 Winners, Laggards, Buys & Sells
Seeking Alpha · 02/26 12:30
argenx SE GAAP EPS of $8.02 beats by $1.70, revenue of $1.29B misses by $10M
Seeking Alpha · 02/26 06:19
Allspring Premier Large Company Growth Fund Q4 2025 Top Contributors And Detractors
Seeking Alpha · 02/24 00:20
Allspring Large Cap Growth Fund Q4 2025 Performance Update
Seeking Alpha · 02/19 05:30
Allspring Growth Fund Q4 2025 Fund Performers And Detractors
Seeking Alpha · 02/13 02:15
Artisan Mid Cap Fund Q4 2025 Performance Discussion And Portfolio Activity
Seeking Alpha · 01/20 03:30
Argenx announces CEO transition
Seeking Alpha · 01/05 12:46
argenx: TED Phase 3 Failure, Vyvgart Growth, And Why I'm Still A Hold
Seeking Alpha · 12/17/2025 20:07
Touchstone Sands Capital International Growth Equity Fund Q3 2025 Portfolio Update
Seeking Alpha · 12/16/2025 12:00
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement
Seeking Alpha · 12/12/2025 21:28
AstraZeneca: A Rare Compound Growth Opportunity In Biopharma
Seeking Alpha · 12/10/2025 15:26
HQH: Seeing Strong Recent Returns While Attractively Discounted
Seeking Alpha · 11/17/2025 15:24
Baron International Growth Fund Q3 2025 Contributors And Detractors
Seeking Alpha · 11/06/2025 10:40
Argenx outlines five registrational readouts in 2026 while expanding VYVGART global reach
Seeking Alpha · 10/30/2025 20:27
Tracking Baker Brothers Portfolio - Q2 2025 Update
Seeking Alpha · 09/16/2025 00:21
More
Webull provides a variety of real-time ARGNF stock news. You can receive the latest news about Argen X through multiple platforms. This information may help you make smarter investment decisions.
About ARGNF
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.